Oncologie Enters $126 Million Deal for China Rights to Cancer Drug

Oncologie Inc., a Boston-Shanghai biopharma, in-licensed greater China rights to lefitolimod, an immunoncology candidate developed by Mologen of Berlin . The two companies also plan a global collaboration for lefitolimod, including a biomarker that Oncologie will develop. Oncology will make an initial $3.7 million payment and invest another $2.5 million in Mologen's shares within one year. In addition, Oncology agreed to pay milestones that total over $120 million plus double-digit royalties on any sales. The two companies will share revenues from any sales, based on their contributions. More details.... Stock Symbol: (F: MGN) Share this with colleagues: // //